Cue Biopharma Inc CUE
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2018-01-02 |
| Shares Out. | 4,050,000 |
| Website | cuebiopharma.com/ ↗ |
| Phone | 13026587581 |
| Employees | 29 |
| Revenue | $5.7M |
| Gross Profit | $5.7M |
| Net Income | -$5.2M |
| Free Cash Flow | -$24.6M |
| Total Assets | $30.9M |
| Total Liabilities | $9.3M |
| Equity | $21.6M |
About Cue Biopharma Inc
Cue Biopharma Inc is a clinical-stage therapeutics company focused on advancing a robust portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its product pipeline includes CUE-221, an anti-IgE antibody candidate being developed for allergic diseases. The company has also developed the Immuno-STAT platform for targeting disease-related T cells and is developing CUE-401, an IL-2 and TGF-B therapeutic candidate for autoimmune diseases.
Cue Biopharma Inc is a publicly traded company under the ticker symbol CUE on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
5 analysts (2026-07-01)